Cell Therapeutics Inc, Ortho Biotech Inc., R. W. Johnson Pharmaceuticals Research Institute deal

CTIC and the two Johnson & Johnson subsidiaries expanded their 1996 agreement to develop lisofylline, an inhibitor of phosphatidic acid, to

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE